Spruce Biosciences, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Spruce Biosciences, Inc. (SPRB) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $355.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-16.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2023-03-16
- Spruce Biosciences, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-12-31 was $105.00K, a 31.25% increase year-over-year.
- Spruce Biosciences, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-09-30 was $84.00K, a 7.69% increase year-over-year.
- Spruce Biosciences, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-06-30 was $84.00K, a 7.69% increase year-over-year.
- Spruce Biosciences, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2022-03-31 was $82.00K, a 6.49% increase year-over-year.
- Spruce Biosciences, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $355.00K, a 13.42% increase from fiscal 2021.
- Spruce Biosciences, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $313.00K, a 374.24% increase from fiscal 2020.
- Spruce Biosciences, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2020 was $66.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2022-12-31 | $105.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $189.00K derived: sum of 2 quarters · filed 2023-03-16 | $273.00K derived: sum of 3 quarters · filed 2023-03-16 | $355.00K 10-K · filed 2023-03-16 |
| 2022-09-30 | $84.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $168.00K derived: sum of 2 quarters · filed 2022-11-10 | $250.00K 10-Q · filed 2022-11-10 | $330.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2022-06-30 | $84.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $166.00K 10-Q · filed 2022-08-10 | $246.00K derived: sum of 3 quarters · filed 2023-03-16 | $324.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2022-03-31 | $82.00K 10-Q · filed 2022-05-11 | $162.00K derived: sum of 2 quarters · filed 2023-03-16 | $240.00K derived: sum of 3 quarters · filed 2023-03-16 | $318.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-12-31 | $80.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $158.00K derived: sum of 2 quarters · filed 2023-03-16 | $236.00K derived: sum of 3 quarters · filed 2023-03-16 | $313.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $78.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $156.00K derived: sum of 2 quarters · filed 2022-11-10 | $233.00K 10-Q · filed 2022-11-10 | $273.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $78.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $155.00K 10-Q · filed 2022-08-10 | $195.00K derived: sum of 3 quarters · filed 2022-08-10 | |
| 2021-03-31 | $77.00K 10-Q · filed 2022-05-11 | $117.00K derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $66.00K 10-K · filed 2022-03-14 | ||
| 2020-09-30 | $26.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |